Vessel co-option in cancer
All solid tumours require a vascular supply in order to progress. Although the ability to
induce angiogenesis (new blood vessel growth) has long been regarded as essential to this …
induce angiogenesis (new blood vessel growth) has long been regarded as essential to this …
Evolving standards of care and new challenges in the management of HER2‐positive breast cancer
GM Choong, GD Cullen… - CA: a cancer journal for …, 2020 - Wiley Online Library
The management of human epidermal growth factor receptor (HER2)–positive breast cancer
(BC) has rapidly evolved over the last 20 years. Major advances have led to US Food and …
(BC) has rapidly evolved over the last 20 years. Major advances have led to US Food and …
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled …
M Martin, FA Holmes, B Ejlertsen, S Delaloge… - The lancet …, 2017 - thelancet.com
Background ExteNET showed that 1 year of neratinib, an irreversible pan-HER tyrosine
kinase inhibitor, significantly improves 2-year invasive disease-free survival after …
kinase inhibitor, significantly improves 2-year invasive disease-free survival after …
[HTML][HTML] Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial
A Chan, B Moy, J Mansi, B Ejlertsen, FA Holmes… - Clinical breast …, 2021 - Elsevier
Abstract Background The ExteNET trial demonstrated improved invasive disease-free
survival (iDFS) with neratinib, an irreversible pan-HER tyrosine kinase inhibitor, versus …
survival (iDFS) with neratinib, an irreversible pan-HER tyrosine kinase inhibitor, versus …
Bevacizumab: a review of its use in advanced cancer
GM Keating - Drugs, 2014 - Springer
The humanized monoclonal antibody bevacizumab (Avastin®) has been available in the EU
since 2005. Results of phase III trials demonstrate that adding intravenous bevacizumab to …
since 2005. Results of phase III trials demonstrate that adding intravenous bevacizumab to …
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial
Background NSABP B-40 was a 3× 2 factorial trial testing whether adding capecitabine or
gemcitabine to docetaxel followed by doxorubicin plus cyclophosphamide neoadjuvant …
gemcitabine to docetaxel followed by doxorubicin plus cyclophosphamide neoadjuvant …
Anti-angiogenic treatment in breast cancer: Facts, successes, failures and future perspectives
Angiogenesis is one of the hallmarks of cancer and a crucial requisite in the development of
tumors. Interrupting this process by blocking the vascular endothelial growth factor (VEGF) …
tumors. Interrupting this process by blocking the vascular endothelial growth factor (VEGF) …
[HTML][HTML] VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside
M Arjaans, CP Schröder, SF Oosting, U Dafni… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Vascular endothelial growth factor (VEGF) pathway targeting agents have been combined
with other anticancer drugs, leading to improved efficacy in carcinoma of the cervix …
with other anticancer drugs, leading to improved efficacy in carcinoma of the cervix …
Current therapies for human epidermal growth factor receptor 2-positive metastatic breast cancer patients
AA Larionov - Frontiers in oncology, 2018 - frontiersin.org
The median survival of patients with human epidermal growth factor receptor 2 (HER2)-
positive metastatic breast cancer (MBC) has more than doubled, since the discovery of …
positive metastatic breast cancer (MBC) has more than doubled, since the discovery of …
Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in …
JR Mackey, M Ramos-Vazquez, O Lipatov… - Journal of Clinical …, 2015 - ascopubs.org
Purpose Currently, antiangiogenic strategies in metastatic breast cancer have demonstrated
modest improvements in progression-free survival (PFS) but not improved quality or duration …
modest improvements in progression-free survival (PFS) but not improved quality or duration …